Updated on 2025/07/05

Information

 

写真a

 
TSUNEYOSHI SHOJI
 
Organization
Kyushu University Hospital Department of Nephrology,Hypertension,and Strokology Assistant Professor
School of Medicine Department of Medicine(Concurrent)
Title
Assistant Professor
Contact information
メールアドレス
Tel
0926425843
External link

Degree

  • Doctor of Philosophy (Medical Science)

Research Interests・Research Keywords

  • Research theme: Fukuoka Peritoneal Dialysis Registry (F-PDR)

    Keyword: Peritoneal Dialysis

    Research period: 2024.4

Papers

  • Predictors of encapsulated peritoneal sclerosis in patients undergoing peritoneal dialysis using neutral-pH dialysate(タイトル和訳中)

    Nakano Toshiaki, Kitamura Hiromasa, Tsuneyoshi Shoji, Tsuchimoto Akihiro, Torisu Kumiko, Tsujikawa Hiroaki, Kawanishi Hideki, Tsuruya Kazuhiko, Kitazono Takanari

    Clinical and Experimental Nephrology   29 ( 2 )   212 - 220   2025.2   ISSN:1342-1751

     More details

    Language:English   Publisher:(一社)日本腎臓学会  

  • Safety and Efficacy of Early Introduction of Angiotensin II Receptor Blockers for Hypertension in Kidney Transplant Recipients: A Retrospective Observational Study Using Propensity Score Matching

    Kubo S., Noguchi H., Hisadome Y., Ueki K., Matsukuma Y., Tsuneyoshi S., Sato Y., Tsuchimoto A., Nakano T., Kaku K., Okabe Y., Nakamura M.

    Transplantation Proceedings   2025   ISSN:00411345

     More details

    Language:English   Publisher:Transplantation Proceedings  

    Kidney transplantation (KTx) is the optimal treatment for end-stage kidney disease, but hypertension after KTx is significant complication affecting graft and patient survival. Although angiotensin II receptor blockers (ARBs) are widely used, the effect of their “early” introduction on outcomes remains unclear. This retrospective observational cohort study compared KTx recipients who started ARBs within the first 14 days post-transplant (early ARB [eARB] group) to those ARBs initiated after three months (conventional group). Propensity score matching was used to align the groups. Blood pressure control, estimated glomerular filtration rate, and serum potassium levels, urinary protein, and adverse events were analyzed. Between 2020 and 2022, 174 patients underwent living-donor KTx. Propensity score matching refined this to 38 matched pairs (76 individuals), which were analyzed. No significant difference in blood pressure control was observed between the two groups at any time point. Results showed that eARB use led to significantly lower urinary protein levels at 3 months compared to the conventional group (P = .019). There were no significant differences in adverse events, including hyperkalemia, rejection, or hypotension, between groups. Potassium-lowering agents were used slightly more in the eARB group, but the difference was not significant. Although eARBs initiation appears safe and potentially beneficial for kidney transplant recipients, further studies are needed to fully understand the long-term implications of this strategy.

    DOI: 10.1016/j.transproceed.2025.05.003

    Scopus

    PubMed

  • Predictors of encapsulated peritoneal sclerosis in patients undergoing peritoneal dialysis using neutral-pH dialysate

    Nakano, T; Kitamura, H; Tsuneyoshi, S; Tsuchimoto, A; Torisu, K; Tsujikawa, H; Kawanishi, H; Tsuruya, K; Kitazono, T

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   2024.10   ISSN:1342-1751 eISSN:1437-7799

     More details

    Language:English   Publisher:Clinical and Experimental Nephrology  

    Background: Encapsulated peritoneal sclerosis (EPS) is a serious complication in patients undergoing peritoneal dialysis (PD). Neutral-pH dialysate is associated with less peritoneal damage and a lower incidence of EPS than conventional PD solution. However, monitoring for peritoneal damage and predicting EPS remain important during PD therapy. Methods: We measured the mesothelial cell area, dialysate-to-plasma ratio of creatinine after 4 h, and concentrations of the potential biological markers effluent fibrin degradation products (eFDPs), cancer antigen-125, and interleukin-6 in the effluent dialysate from patients who had been undergoing PD therapy for > 5 years in our hospital. These biomarkers were obtained from the drainage fluid of the final measurement of peritoneal equilibration testing before withdrawal from PD therapy. The concentrations of these potential biomarkers were measured in 39 patients who withdrew from PD therapy and were enrolled in the study. Results: Three participants developed EPS after withdrawing PD. The dialysate-to-plasma ratio of creatinine, area of mesothelial cells, and interleukin-6 appearance rate in participants who developed EPS tended to be higher than those in patients who did not, but there were no significant differences. Significantly more eFDPs were in participants who developed EPS than in those who did not (138.5 ± 15.1 vs. 32.9 ± 7.4 µg/mL, P = 0.002). There was no difference in the cancer antigen-125 appearance rate between the groups. A cut-off value of eFDPs ≥ 119.1 µg/mL was optimal for predicting EPS (P = 0.006, specificity = 0.972, sensitivity = 1.000). Conclusion: This study shows that eFDPs may be a useful biological marker for predicting EPS in patients undergoing PD using neutral-pH dialysate.

    DOI: 10.1007/s10157-024-02565-9

    Web of Science

    Scopus

    PubMed

Presentations

▼display all

MISC

Professional Memberships

  • 日本内科学会

  • 日本腎臓学会

  • 日本透析医学会

Educational Activities

  • 医学部生の臨床実習(ベッドサイド実習、クリニカルクラークシップ)指導
    OSCE実習指導
    OSCE評価